Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...